4th Quarter - Amendment

ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) for ASTELLAS PHARMA US, INC.

Firm
Client
Income
$50,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 21, 2020 $50,000 Replaced
4th Quarter - Amendment (this page) Jan 22, 2020 $50,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

House and Senate Appropriations for FY ending Sept. 30, 2019

LobbyistCovered position, as disclosed
STEVEN E IRIZARRY —
VINCENT A. ROBERTI, SR. —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Issues related to drug pricing and value, generally

LobbyistCovered position, as disclosed
STEVEN E IRIZARRY —
VINCENT A. ROBERTI, SR. —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Law Enforcement/Crime/Criminal Justice LAW

Issues related to lobbying disclosure for US affiliates

LobbyistCovered position, as disclosed
STEVEN E IRIZARRY —
VINCENT A. ROBERTI, SR. —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Issues related to Medicare Part D, including non-interference, rebate policy issues Issues related to drug pricing, value, and transparency, generally

LobbyistCovered position, as disclosed
STEVEN E IRIZARRY —
VINCENT A. ROBERTI, SR. —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.